However, nimotuzumab, a humanized IgG1 monoclonal anti-ERBB1/EGFR antibody, with specific activity against EGFRvIII, has shown similar outcomes to more intensive chemotherapy regimens, with fewer side effects, low toxicities, and no need for prolonged hospitalization, thus leading to the continued investigation of nimotuzumab as an adjuvant therapy in pediatric glioma [112]. The gene discussed is EGFR; the disease is glioma.